Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Avalyn PharmaAVLN -1.01%11 Market Cap is $1,263.49 Mil as of Aug. 03, 2026. GuruFocus rates AVLN with a GF Score™ of 11/100. Among 1,423 Biotechnology companies, Avalyn Pharma ranks better than 83.49% on this metric.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Avalyn Pharma's share price for the quarter that ended in Dec. 2025 was $0. Avalyn Pharma's Shares Outstanding (EOP) for the quarter that ended in Dec. 2025 was 41.81 Mil. Therefore, Avalyn Pharma's market cap for the quarter that ended in Dec. 2025 was $0.00 Mil.
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Avalyn Pharma's Enterprise Value for Today is $1,156.77 Mil.
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Avalyn Pharma Market Cap Related Terms
Avalyn Pharma Market Cap Historical Data
* Premium members only.
The historical data trend for Avalyn Pharma's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Avalyn Pharma Market Cap Chart
Avalyn Pharma Annual Data
Trend
Dec24
Dec25
Market Cap
0.00
0.00
Avalyn Pharma Semi-Annual Data
Dec24
Dec25
Market Cap
0.00
0.00
AVLN vs TRAX, IMTX, ARDX: Market Cap Comparison
For the Biotechnology subindustry, Avalyn Pharma's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Avalyn Pharma Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Avalyn Pharma's Market Cap distribution charts can be found below:
* The bar in red indicates where Avalyn Pharma's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Avalyn Pharma's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Avalyn Pharma (AVLN) has a Market Cap of $1,263.49 Mil as of Aug. 03, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Avalyn Pharma and its competitors. According to the industry distribution chart, Avalyn Pharma ranks #235 out of 1423 companies in the Biotechnology industry, placing it in the top 16.5%.
Is Avalyn Pharma's Market Cap too high?
Avalyn Pharma's current Market Cap is $1,263.49 Mil. The Biotechnology industry median Market Cap is 113.28. Avalyn Pharma's value of $1,263.49 Mil is 1015.3% above this industry median. Based on the distribution chart, Avalyn Pharma ranks #235 out of 1423 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Avalyn Pharma has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Avalyn Pharma's Market Cap compare to TRAX and IMTX?
According to the Biotechnology industry distribution chart, Avalyn Pharma ranks #235 out of 1423 companies for Market Cap. This places Avalyn Pharma in the top 17% of its industry — outperforming the majority of peers. The industry median Market Cap is 113.28. Avalyn Pharma's value of $1,263.49 Mil is 1015.3% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 113.28, based on 1,423 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Avalyn Pharma's current Market Cap of $1,263.49 Mil is 1015.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Avalyn Pharma and its competitors. For the Biotechnology industry, the median Market Cap is 113.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Avalyn Pharma's current Market Cap is $1,263.49 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Avalyn Pharma stock overvalued right now?
Avalyn Pharma (AVLN) has a current Market Cap of $1,263.49 Mil. The current Market Cap is $1,263.49 Mil and 1015.3% above the Biotechnology industry median of 113.28. Avalyn Pharma's overall GF Score™ is 11/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Avalyn Pharma (AVLN), the current Market Cap is $1,263.49 Mil as of Aug. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Avalyn Pharma Inc is a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases (ILDs). Its current pipeline is focused on treating pulmonary fibrosis, a life-threatening disease with a median survival of three to five years, which is a significantly shorter prognosis than that observed for many forms of cancer. Its flagship programs include AP01 and AP02, which are inhaled formulations of pirfenidone and nintedanib being developed for conditions such as progressive pulmonary fibrosis and idiopathic pulmonary fibrosis. The company has one operating and reportable segment, which is the business of developing and commercializing targeted therapies for rare lung diseases.
11GF Score
Get the complete analysis for AVLN
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AVLN has been successfully added to your 
